Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMT-205
- Development stage
- Preclinical
- Lead developer
- Memento Medicines
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
MMT-205 (formerly MT-103) is an investigational bispecific antibody being developed for the treatment of retinal vascular diseases, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Originally co-developed by South Korean biotechs MabTics and Curacle, the asset was licensed globally by Memento Medicines in 2026. MMT-205 is designed to simultaneously activate the Tie2 receptor and inhibit the VEGF pathway. By directly agonizing Tie2, the drug aims to enhance retinal blood vessel integrity and reduce vascular leakage, while its anti-VEGF component blocks pathological neovascularization. MMT-205 is currently undergoing IND-enabling studies, with first-in-human clinical trials planned to initiate in 2027.
02
Targets
Beyond the preview
Go deeper on MMT-205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMT-205.